CyDex, a US company working in drug delivery technologies, has signed announced an agreement with Merck regarding its advanced formulation system Captisol.
According to CyDex, the Agreement provides Merck with the ability to utilise Captisol in limited human clinical development studies.
"We are excited that Merck has selected Captisol as a drug delivery vehicle to enable the scientific evaluation of important drug candidates," said Edward W. Mehrer, president and CEO of CyDex. "Merck's impressive scientific capabilities and global presence make it an outstanding partner for CyDex."
Under terms of the agreement, CyDex grants Merck the ability to use Captisol in early development clinical studies and several compounds have already been selected as potential candidates for the Captisol technology.
According to CyDex, Captisol enables 'the safe, effective delivery of medications by improving the solubility, stability and bioavailability of drug compounds.'
Captisol is a doughnut-shaped molecule that complexes water insoluble active drugs in its central cavity. When given by injection, a Captisol-Enabled formulation helps carry a drug into the patient's bloodstream, allowing the active ingredient to produce its desired pharmacological effect.
Currently, two Captisol-Enabled formulations have been approved and are commercially available in the United States and Europe.